• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

程序性死亡-1配体-1(PDL1)表达与II/III期胃癌患者的预后相关。

Programmed Death-1 Ligand-1 (PDL1) Expression Is Associated with the Prognosis of Patients with Stage II/III Gastric Cancer.

作者信息

Tamura Tatsuro, Ohira Masaichi, Tanaka Hiroaki, Muguruma Kazuya, Toyokawa Takahiro, Kubo Naoshi, Sakurai Katsunobu, Amano Ryosuke, Kimura Kenjiro, Shibutani Masatsune, Maeda Kiyoshi, Hirakawa Kosei

机构信息

Department of Surgical Oncology, Osaka City University, Graduate School of Medicine, Osaka, Japan.

Department of Surgical Oncology, Osaka City University, Graduate School of Medicine, Osaka, Japan

出版信息

Anticancer Res. 2015 Oct;35(10):5369-76.

PMID:26408698
Abstract

BACKGROUND/AIM: The cell surface receptor programmed death-1 (PD1) and its ligand (PDL1) have been detected in various cancer types. It has been reported that expression of PDL1 and PD1 in a tumor is associated with poor prognosis of the patient. In the present study, we retrospectively examined tumor expression of PDL1 and intratumoral PD1(+) cell infiltration, and assessed their relationship with patient prognosis according to the pathological stage of gastric cancer.

MATERIALS AND METHODS

PDL1 and PD1 expression in primary tumors from 431 patients was evaluated using immunohistochemistry. The association between the expression of PDL1/PD1 and clinicopathological features was assessed.

RESULTS

High expression of PDL1 was observed in 128 (29.6%) patients. PDL1 expression was correlated with tumor infiltration of PD1(+) cells. In multivariate analysis, PDL1 expression was associated with worse overall survival. In subset analysis, PDL1 expression was significantly associated with survival in patients with stage II/III gastric cancer. In conclusion, PDL1 was an independent prognostic factor for patients with stage II/III gastric cancer. Our results suggested that patients with stage II/III gastric cancer might be appropriate for PD1/PDL1-targeted therapy.

摘要

背景/目的:在多种癌症类型中已检测到细胞表面受体程序性死亡蛋白1(PD1)及其配体(PDL1)。据报道,肿瘤中PDL1和PD1的表达与患者预后不良相关。在本研究中,我们回顾性检测了PDL1的肿瘤表达及肿瘤内PD1(+)细胞浸润情况,并根据胃癌的病理分期评估它们与患者预后的关系。

材料与方法

采用免疫组织化学法评估431例患者原发性肿瘤中PDL1和PD1的表达。评估PDL1/PD1表达与临床病理特征之间的关联。

结果

128例(29.6%)患者观察到PDL1高表达。PDL1表达与PD1(+)细胞的肿瘤浸润相关。多因素分析显示,PDL1表达与总生存期较差相关。亚组分析中,PDL1表达与II/III期胃癌患者的生存显著相关。总之,PDL1是II/III期胃癌患者的独立预后因素。我们的结果提示,II/III期胃癌患者可能适合接受PD1/PDL1靶向治疗。

相似文献

1
Programmed Death-1 Ligand-1 (PDL1) Expression Is Associated with the Prognosis of Patients with Stage II/III Gastric Cancer.程序性死亡-1配体-1(PDL1)表达与II/III期胃癌患者的预后相关。
Anticancer Res. 2015 Oct;35(10):5369-76.
2
Clinical Significance of and in Human Breast Cancer.[文中未明确的两个因素]在人类乳腺癌中的临床意义。
Anticancer Res. 2017 Aug;37(8):4249-4254. doi: 10.21873/anticanres.11817.
3
The Clinical Significance of PD-L1/PD-1 Expression in Gastroenteropancreatic Neuroendocrine Neoplasia.PD-L1/PD-1表达在胃肠胰神经内分泌肿瘤中的临床意义
Ann Clin Lab Sci. 2019 Sep;49(4):448-456.
4
Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors.程序性细胞死亡配体1(PD-L1)在胃癌中的表达及其与临床病理因素的关系。
Int J Clin Exp Pathol. 2015 Sep 1;8(9):11084-91. eCollection 2015.
5
Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome.程序性死亡配体1在三阴性乳腺癌中的表达与肿瘤浸润淋巴细胞及预后改善相关。
Histopathology. 2016 Jul;69(1):25-34. doi: 10.1111/his.12904. Epub 2016 Jan 13.
6
PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer.肿瘤浸润淋巴细胞中的 PD1 蛋白表达而非肿瘤细胞中的 PDL1 预测三阴性乳腺癌的生存。
Cancer Biol Ther. 2018 May 4;19(5):373-380. doi: 10.1080/15384047.2018.1423919. Epub 2018 Feb 16.
7
PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival.程序性死亡受体1(PD1)和程序性死亡配体1(PDL1)在原发性中枢神经系统弥漫性大B细胞淋巴瘤中表达频繁,且PD1表达预示着较差的生存率。
Hematol Oncol. 2017 Dec;35(4):487-496. doi: 10.1002/hon.2375. Epub 2016 Dec 13.
8
Expression and significance of CD47, PD1 and PDL1 in T-cell acute lymphoblastic lymphoma/leukemia.CD47、PD1和PDL1在T细胞急性淋巴细胞白血病/淋巴瘤中的表达及意义
Pathol Res Pract. 2019 Feb;215(2):265-271. doi: 10.1016/j.prp.2018.10.021. Epub 2018 Nov 2.
9
[Immunotherapy in non-small cell lung cancer: inhibition of PD1/PDL1 pathway].[非小细胞肺癌中的免疫疗法:PD1/PDL1 通路的抑制]
Rev Pneumol Clin. 2015 Feb;71(1):44-56. doi: 10.1016/j.pneumo.2014.11.004. Epub 2015 Feb 14.
10
Correlation between infiltration of FOXP3+ regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer.胃癌组织中 FOXP3+调节性 T 细胞浸润与 B7-H1 表达的相关性。
Exp Mol Pathol. 2014 Jun;96(3):284-91. doi: 10.1016/j.yexmp.2014.03.005. Epub 2014 Mar 20.

引用本文的文献

1
FAM49B mediates tumor progression and poor prognosis of gastric cancer through activating PI3K/AKT pathway.FAM49B通过激活PI3K/AKT信号通路介导胃癌的肿瘤进展和不良预后。
J Mol Histol. 2025 Sep 3;56(5):291. doi: 10.1007/s10735-025-10589-y.
2
Programmed Death Ligand-1 Expression in Gastric Cancer Cases in Zambia.赞比亚胃癌病例中程序性死亡配体-1的表达
J Agric Biomed Sci. 2025 Apr-Jun;9(2). doi: 10.53974/unza.jabs.9.2.1492. Epub 2025 Jun 4.
3
Prognostic Value of PD-L1, BAP-1 and ILK in Pleural Mesothelioma.PD-L1、BAP-1和整合素连接激酶在胸膜间皮瘤中的预后价值
J Clin Med. 2024 Dec 2;13(23):7322. doi: 10.3390/jcm13237322.
4
, a bridge between oral health and immune evasion in gastric cancer.,胃癌中口腔健康与免疫逃逸之间的桥梁。
Front Oncol. 2024 May 14;14:1403089. doi: 10.3389/fonc.2024.1403089. eCollection 2024.
5
Soluble PD-L1 as a diagnostic and prognostic biomarker in resectable gastric cancer patients.可溶性 PD-L1 作为可切除胃癌患者的诊断和预后生物标志物。
Gastric Cancer. 2023 Nov;26(6):934-946. doi: 10.1007/s10120-023-01429-7. Epub 2023 Sep 5.
6
Zinc Finger Proteins in the War on Gastric Cancer: Molecular Mechanism and Clinical Potential.锌指蛋白在胃癌战争中的作用:分子机制和临床潜力。
Cells. 2023 May 4;12(9):1314. doi: 10.3390/cells12091314.
7
The heterogeneity of PD-L1 protein in gastric cancer: expression and distribution characteristics.胃癌中PD-L1蛋白的异质性:表达及分布特征
Heliyon. 2022 Dec 20;8(12):e12456. doi: 10.1016/j.heliyon.2022.e12456. eCollection 2022 Dec.
8
Loss of SATB2 expression correlates with cytokeratin 7 and PD-L1 tumor cell positivity and aggressiveness in colorectal cancer.SATB2 表达缺失与结直肠癌中细胞角蛋白 7 和 PD-L1 肿瘤细胞阳性和侵袭性相关。
Sci Rep. 2022 Nov 9;12(1):19152. doi: 10.1038/s41598-022-22685-0.
9
TERC suppresses PD-L1 expression by downregulating RNA binding protein HuR.TERC 通过下调 RNA 结合蛋白 HuR 来抑制 PD-L1 的表达。
Sci China Life Sci. 2022 Dec;65(12):2505-2516. doi: 10.1007/s11427-021-2085-9. Epub 2022 Jun 1.
10
Programmed Death-Ligand 1 (PD-L1) Positivity and Factors Associated with Poor Prognosis in Patients with Gastric Cancer: An Umbrella Meta-Analysis.程序性死亡配体1(PD-L1)阳性与胃癌患者预后不良相关因素:一项伞状荟萃分析
Cureus. 2022 Apr 5;14(4):e23845. doi: 10.7759/cureus.23845. eCollection 2022 Apr.